

10556229a.trn

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 02	LMEDLINE coverage updated
NEWS	3	JUL 02	SCISEARCH enhanced with complete author names
NEWS	4	JUL 02	CHEMCATS accession numbers revised
NEWS	5	JUL 02	CA/CAPplus enhanced with utility model patents from China
NEWS	6	JUL 16	CAplus enhanced with French and German abstracts
NEWS	7	JUL 18	CA/CAPplus patent coverage enhanced
NEWS	8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	9	JUL 30	USGENE now available on STN
NEWS	10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	11	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	12	AUG 13	CA/CAPplus enhanced with additional kind codes for granted patents
NEWS	13	AUG 20	CA/CAPplus enhanced with CAS indexing in pre-1907 records
NEWS	14	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	15	AUG 27	USPATOLD now available on STN
NEWS	16	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	17	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	18	SEP 13	FORIS renamed to SOFIS
NEWS	19	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	20	SEP 17	CA/CAPplus enhanced with printed CA page images from 1967-1998
NEWS	21	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS	22	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	23	OCT 02	CA/CAPplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	24	OCT 19	BEILSTEIN updated with new compounds
NEWS EXPRESS	19	SEPTEMBER 2007:	CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer

10556229a.trn

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 10:17:47 ON 09 NOV 2007

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:18:03 ON 09 NOV 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 NOV 2007 HIGHEST RN 952702-46-4  
DICTIONARY FILE UPDATES: 8 NOV 2007 HIGHEST RN 952702-46-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10556229a.str



```

chain nodes :
10 11 12 13 14 15 18 21 22 25
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
1-25 5-21 6-10 10-11 10-22 11-12 12-13 12-15 13-14 13-18
ring bonds :
1-2 1-7 2-3 3-4 4-8 5-6 5-9 6-7 7-8 8-9
exact/norm bonds :
1-25 5-6 5-9 5-21 6-7 6-10 8-9 10-22 12-13 12-15 13-18
exact bonds :
10-11 11-12 13-14
normalized bonds :
1-2 1-7 2-3 3-4 4-8 7-8
isolated ring systems :
containing 1 :

```

G1:H,Ak,CH3

G2:X,Ak,CN,NH2,NO2,Hy

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 18:CLASS 21:CLASS 22:CLASS
25:CLASS


```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 H, Ak, Me

G2 X, Ak, CN, NH2, NO2, Hy

Structure attributes must be viewed using STN Express query preparation.

=&gt; s l1

SAMPLE SEARCH INITIATED 10:18:21 FILE 'REGISTRY'  
 SAMPLE SCREEN SEARCH COMPLETED - 1280 TO ITERATE

100.0% PROCESSED 1280 ITERATIONS  
 SEARCH TIME: 00.00.01

6 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
 BATCH \*\*COMPLETE\*\*  
 PROJECTED ITERATIONS: 23454 TO 27746  
 PROJECTED ANSWERS: 6 TO 266

L2 6 SEA SSS SAM L1

=&gt; s l1 sss full

FULL SEARCH INITIATED 10:18:28 FILE 'REGISTRY'  
 FULL SCREEN SEARCH COMPLETED - 25941 TO ITERATE

100.0% PROCESSED 25941 ITERATIONS  
 SEARCH TIME: 00.00.02

106 ANSWERS

L3 106 SEA SSS FUL L1

=&gt; FIL HCAPLUS

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
172.10	172.31

FULL ESTIMATED COST

FILE 'HCAPLUS' ENTERED AT 10:18:37 ON 09 NOV 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

10556229a.trn

The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Nov 2007 VOL 147 ISS 21

FILE LAST UPDATED: 8 Nov 2007 (20071108/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 5 L3

=> s l4 and py<=2003

23955823 PY<=2003

L5 0 L4 AND PY<=2003

=> d l4 ibib abs hitstr tot

L4 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:1146647 HCAPLUS

DOCUMENT NUMBER: 147:448636

TITLE: Preparation of indoles, indazoles, benzimidazoles and their analogs as chemokine receptor CXCR4 and CCR7 inhibitors

INVENTOR(S): Thomas, William D.; Leleti, Manmohan Reddy; Pennell, Andrew M. K.

PATENT ASSIGNEE(S): Chemocentryx, Inc., USA

SOURCE: PCT Int. Appl., 142pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007115231	A2	20071011	WO 2007-US65729	20070330
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.:

US 2006-787925P

P 20060330

GI



AB Title compds. I [wherein R<sup>1</sup> - R<sup>4</sup> independently = H, halo, alkyl, etc.; R<sup>5</sup>, R<sup>6</sup> independently = H, alkyl, cycloalkyl, etc.; Z = C(O), C(O)O, CONH, etc.; m, n = 1-6; ring A = (un)substituted fused 5-membered heteroaryl or heterocycloalkyl; ring B = (un)substituted fused 6-membered (hetero)aryl or (hetero)cycloalkyl; Ar = (un)substituted (hetero)aryl; p = 0-1] and pharmaceutically acceptable salts, hydrates and N-oxides thereof, which can inhibit the binding of the SDF-1 chemokine to the chemokine receptor CXCR4 and/or the binding of the SDF-1 or I-TAC chemokines to the chemokine receptor CXCR7, were prepared For instance, II was synthesized and had IC<sub>50</sub> < 1 μM for both CXCR4 and CXCR7 receptors in chemotaxis or binding assays. The invented compds. and their pharmaceutical compns. are useful for the treatment of CXCR4-mediated diseases or conditions.


IT 952186-47-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indoles, indazoles, benzimidazoles and their analogs as chemokine receptor CXCR4 and CCR7 inhibitors)

RN 952186-47-9 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[2-(cyclohexylmethylamino)ethyl]-6,7-difluoro- (CA INDEX NAME)



L4 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:703476 HCAPLUS

DOCUMENT NUMBER: 147:118229

TITLE: Benzimidazole compounds and their preparation, pharmaceutical compositions and use in the treatment of VR1-mediated diseases

INVENTOR(S): Besidski, Yevgeni; Griffin, Andrew; Labrecque, Denis;

11/09/2007

Page 6



Johnstone, Shawn; Jones, Paul; Kers, Inger; Nyloef, Martin; Skogholm, Karin  
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.  
 SOURCE: PCT Int. Appl., 89pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007073303	A2	<del>20070628</del>	WO 2006-SE1467	<del>20061221</del>
WO 2007073303	A3	20070830		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2005-753604P P 20051223  
 OTHER SOURCE(S): MARPAT 147:118229  
 GI



AB The invention relates to new compds. formula I or salts, solvates or solvated salts thereof, processes for their preparation and to intermediates used in the preparation thereof, pharmaceutical compns. containing said compds. and to the use of said compds. in therapy. Compds. of formula II wherein R1 is NO2, CN, halo, and acetyl; R2 is (un)substituted Ph, (un)substituted

heteroaryl, (un)substituted PhCH<sub>2</sub>, and (un)substituted PhOCH<sub>2</sub>; R<sub>3</sub> is H and F; R<sub>4</sub> is Me, MeOCO, and Et; R<sub>2</sub>R<sub>4</sub> taken together may form (mono/bi)cyclic ring; and their salts, solvates and solvated salts thereof, are claimed. Example compound II was prepared by a general procedure (procedure given). All the invention compds. were evaluated for their VR1 inhibitory activity.

IT 942937-12-4P 942937-13-5P 942937-14-6P  
 942937-15-7P 942937-16-8P 942937-17-9P  
 942937-18-0P 942937-19-1P 942937-20-4P  
 942937-21-5P 942937-22-6P 942937-23-7P  
 942937-24-8P 942937-25-9P 942937-26-0P  
 942937-27-1P 942937-28-2P 942937-29-3P  
 942937-30-6P 942937-31-7P 942937-32-8P  
 942937-33-9P 942937-34-0P 942937-36-2P  
 942937-37-3P 942937-38-4P 942937-39-5P  
 942937-41-9P 942937-43-1P 942937-45-3P  
 942937-47-5P 942937-49-7P 942937-50-0P  
 942937-52-2P 942937-54-4P 942937-56-6P  
 942937-58-8P 942937-59-9P 942937-60-2P  
 942937-62-4P 942937-64-6P 942937-65-7P  
 942937-66-8P 942937-67-9P 942937-69-1P  
 942937-70-4P 942937-72-6P 942937-74-8P  
 942937-80-6P 942937-82-8P 942937-84-0P  
 942937-86-2P 942937-88-4P 942937-90-8P  
 942937-92-0P 942937-94-2P 942937-96-4P  
 942937-97-5P 942937-99-7P 942938-01-4P  
 942938-03-6P 942938-05-8P 942938-07-0P  
 942938-08-1P 942938-10-5P 942938-12-7P  
 942938-14-9P 942938-15-0P 942938-16-1P  
 942938-17-2P 942938-18-3P 942938-19-4P  
 942938-79-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzimidazole compds. useful in therapy of VR1 - mediated diseases)

RN 942937-12-4 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[(1S)-1-[4-(1-methylethoxy)phenyl]ethyl]-7-nitro- (CA INDEX NAME)

Absolute stereochemistry.




RN 942937-13-5 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[(1S)-1-[4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl]ethyl]-7-nitro- (CA INDEX NAME)

Absolute stereochemistry.




10556229a.trn



RN 942937-14-6 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[(1S)-1-[4-(2-fluoroethoxy)phenyl]ethyl]-7-nitro- (CA INDEX NAME)


Absolute stereochemistry.



RN 942937-15-7 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[(1S)-1-[4-[(1-methyl-2-propyn-1-yl)oxy]phenyl]ethyl]-7-nitro- (CA INDEX NAME)


Absolute stereochemistry.



RN 942937-16-8 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[(1S)-1-[4-(2-methoxy-1-methylethoxy)phenyl]ethyl]-7-nitro- (CA INDEX NAME)

Absolute stereochemistry.




RN 942937-17-9 HCAPLUS

10556229a.trn


CN 1H-Benzimidazole-1-acetamide, N-[(1S)-1-(4-ethoxyphenyl)ethyl]-7-nitro-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 942937-18-0 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, 7-nitro-N-[1-[6-(2,2,2-trifluoroethoxy)-3-pyridinyl]ethyl]- (CA INDEX NAME)




RN 942937-19-1 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, 7-chloro-N-[1-[6-(2,2,2-trifluoroethoxy)-3-pyridinyl]ethyl]- (CA INDEX NAME)




RN 942937-20-4 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[1-[6-(2,2-difluoroethoxy)-3-pyridinyl]ethyl]-7-nitro- (CA INDEX NAME)




RN 942937-21-5 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, 7-nitro-N-[1-[6-(2,2,3,3-tetrafluoropropoxy)-3-pyridinyl]ethyl]- (CA INDEX NAME)




RN 942937-22-6 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, 7-chloro-N-[1-[6-(2,2,3,3-tetrafluoropropoxy)-3-pyridinyl]ethyl]- (CA INDEX NAME)



RN 942937-23-7 HCAPLUS


CN 1H-Benzimidazole-1-acetamide, N-[1-[6-(cyclopentyloxy)-3-pyridinyl]ethyl]- 7-nitro- (CA INDEX NAME)



RN 942937-24-8 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[1-[4-[(2S)-2-methoxypropoxy]phenyl]ethyl]- 7-nitro- (CA INDEX NAME)

Absolute stereochemistry.




RN 942937-25-9 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[1-[4-[(1S)-1-methylpropoxy]phenyl]ethyl]- 7-nitro- (CA INDEX NAME)


Absolute stereochemistry.

10556229a.trn




RN 942937-26-0 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[1-[4-(chlorodifluoromethyl)phenyl]ethyl]-7-nitro- (CA INDEX NAME)




RN 942937-27-1 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, 7-chloro-N-[1-[4-(chlorodifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)




RN 942937-28-2 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, 7-chloro-N-[1-[4-(2,2-difluoroethoxy)phenyl]ethyl]- (CA INDEX NAME)




RN 942937-29-3 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[1-[4-(2,2-difluoroethoxy)phenyl]ethyl]-7-nitro- (CA INDEX NAME)




RN 942937-30-6 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, 7-chloro-N-[1-[4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl]ethyl]- (CA INDEX NAME)




RN 942937-31-7 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, 7-acetyl-N-[1-[4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl]ethyl]- (CA INDEX NAME)




RN 942937-32-8 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, 7-nitro-N-[1-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]ethyl]- (CA INDEX NAME)




RN 942937-33-9 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, 7-chloro-N-[1-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]ethyl]- (CA INDEX NAME)




RN 942937-34-0 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, 7-cyano-N-[1-[4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl]ethyl]- (CA INDEX NAME)




RN 942937-36-2 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, 7-cyano-N-[1-[4-(2,2,2-trifluoroethoxy)phenyl]ethyl]- (CA INDEX NAME)




RN 942937-37-3 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[1-[5-chloro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-pyridinyl]ethyl]-7-nitro- (CA INDEX NAME)




RN 942937-38-4 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, 7-cyano-N-[1-[4-[2-fluoro-1-(fluoromethyl)ethoxy]-2-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)




RN 942937-39-5 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[1-[2-chloro-4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl]ethyl]-7-cyano- (CA INDEX NAME)




RN 942937-41-9 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, 7-nitro-N-[1-[5-(trifluoromethyl)-2-pyridinyl]propyl]- (CA INDEX NAME)



RN 942937-43-1 HCAPLUS


CN 1H-Benzimidazole-1-acetamide, 7-nitro-N-[1-[5-(trifluoromethyl)-2-pyridinyl]ethyl]- (CA INDEX NAME)



RN 942937-45-3 HCAPLUS


CN 1H-Benzimidazole-1-acetamide, 7-chloro-N-[1-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]ethyl]- (CA INDEX NAME)

10556229a.trn




RN 942937-47-5 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[1-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]ethyl]-7-nitro- (CA INDEX NAME)




RN 942937-49-7 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[1-[5-chloro-6-(2-fluoroethoxy)-3-pyridinyl]ethyl]-7-nitro- (CA INDEX NAME)



RN 942937-50-0 HCAPLUS


CN 1H-Benzimidazole-1-acetamide, 7-chloro-N-[1-[4-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)




RN 942937-52-2 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, 7-chloro-N-[1-[6-(1-methylethoxy)-3-pyridinyl]ethyl]- (CA INDEX NAME)







RN 942937-54-4 HCAPLUS  
 CN 1H-Benzimidazole-1-acetamide, 7-nitro-N-[1-[4-(trifluoromethoxy)phenyl]ethyl]- (CA INDEX NAME)




RN 942937-56-6 HCAPLUS  
 CN 1H-Benzimidazole-1-acetamide, 7-nitro-N-[1-[4-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)




RN 942937-58-8 HCAPLUS  
 CN 1H-Benzimidazole-1-acetamide, N-[1-[6-(1-methylethoxy)-3-pyridinyl]ethyl]-7-nitro- (CA INDEX NAME)




RN 942937-59-9 HCAPLUS  
 CN 1H-Benzimidazole-1-acetamide, N-[1-[4-(cyclopentyloxy)-3-fluorophenyl]ethyl]-7-nitro- (CA INDEX NAME)




RN 942937-60-2 HCAPLUS  
 CN 1H-Benzimidazole-1-acetamide, N-[1-(4-cyclopropylphenyl)ethyl]-7-nitro-  
 (CA INDEX NAME)



RN 942937-62-4 HCAPLUS  
 CN 1H-Benzimidazole-1-acetamide, N-[1-(4-ethynylphenyl)ethyl]-7-nitro- (CA  
 INDEX NAME)




RN 942937-64-6 HCAPLUS  
 CN 1H-Benzimidazole-1-acetamide, 7-chloro-N-[1-(4-ethynylphenyl)ethyl]- (CA  
 INDEX NAME)




RN 942937-65-7 HCAPLUS  
 CN 1H-Benzimidazole-1-acetamide, N-[1-[5-(cyclopropylmethoxy)-2-  
 pyridinyl]ethyl]-7-nitro- (CA INDEX NAME)

10556229a.trn



RN 942937-66-8 HCAPLUS


CN 1H-Benzimidazole-1-acetamide, N-[1-[5-(1-methylethoxy)-2-pyridinyl]ethyl]-7-nitro- (CA INDEX NAME)



RN 942937-67-9 HCAPLUS


CN 1H-Benzimidazole-1-acetamide, 7-acetyl-N-[(1S)-1-[4-(1,1-dimethylethyl)phenyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 942937-69-1 HCAPLUS


CN 1H-Benzimidazole-1-acetamide, N-[1-[4-[(1-methyl-4-piperidinyl)oxy]-3-(trifluoromethyl)phenyl]ethyl]-7-nitro- (CA INDEX NAME)



RN 942937-70-4 HCAPLUS


CN 1H-Benzimidazole-1-acetamide, N-[1-[4-[(2S)-2-methoxypropoxy]-3-(trifluoromethyl)phenyl]ethyl]-7-nitro- (CA INDEX NAME)

Absolute stereochemistry.




RN 942937-72-6 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[1-methyl-2-[3-(trifluoromethyl)phenoxy]ethyl]-7-nitro- (CA INDEX NAME)



RN 942937-74-8 HCAPLUS


CN 1H-Benzimidazole-1-acetamide, N-[2-(4-chlorophenyl)-1-methylethyl]-7-nitro- (CA INDEX NAME)



RN 942937-80-6 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[(1S)-1-[4-(1,1-dimethylethyl)phenyl]ethyl]-6,7-difluoro- (CA INDEX NAME)


Absolute stereochemistry.




RN 942937-82-8 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[1-[4-(1,1-dimethylethyl)phenyl]ethyl]-6,7-difluoro- (CA INDEX NAME)


10556229a.trn




RN 942937-84-0 HCAPLUS  
CN 1H-Benzimidazole-1-acetamide, 7-cyano-N-[1-[4-(1,1-dimethylethyl)phenyl]ethyl]- (CA INDEX NAME)




RN 942937-86-2 HCAPLUS  
CN 1H-Benzimidazole-1-acetamide, 7-cyano-N-[1-[4-(1-methylethyl)phenyl]ethyl]- (CA INDEX NAME)



RN 942937-88-4 HCAPLUS  
CN 1H-Benzimidazole-1-acetamide, 7-cyano-N-[1-[4-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)



RN 942937-90-8 HCAPLUS  
CN 1H-Benzimidazole-1-acetamide, 7-fluoro-N-[1-[4-(1-methylethyl)phenyl]ethyl]- (CA INDEX NAME)




10556229a.trn

RN 942937-92-0 HCAPLUS


CN 1H-Benzimidazole-1-acetamide, 7-cyano-N-[(1S)-1-[4-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 942937-94-2 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, 6,7-difluoro-N-[1-[4-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)




RN 942937-96-4 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, 7-cyano-N-[1-[4-(trifluoromethoxy)phenyl]ethyl]- (CA INDEX NAME)




RN 942937-97-5 HCAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[2-(6,7-difluoro-1H-benzimidazol-1-yl)acetyl]amino]-4-(1,1-dimethylethyl)-, methyl ester (CA INDEX NAME)




RN 942937-99-7 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, 7-fluoro-N-[1-[4-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)




RN 942938-01-4 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, 7-cyano-N-[1-[5-(1,1-dimethylethyl)-2-pyridinyl]ethyl]- (CA INDEX NAME)




RN 942938-03-6 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, 7-cyano-N-[1-[3-fluoro-4-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)




RN 942938-05-8 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[1-[5-(1,1-dimethylethyl)-2-thienyl]ethyl]-6,7-difluoro- (CA INDEX NAME)




RN 942938-07-0 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[1-[5-(1,1-dimethylethyl)-2-thienyl]ethyl]-7-fluoro- (CA INDEX NAME)




RN 942938-08-1 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, 7-cyano-N-[1-[5-(1,1-dimethylethyl)-2-thienyl]ethyl]- (CA INDEX NAME)




RN 942938-10-5 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, 7-cyano-N-[1-[6-(1,1-dimethylethyl)-2-methoxy-3-pyridinyl]ethyl]- (CA INDEX NAME)




RN 942938-12-7 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[1-[6-(1,1-dimethylethyl)-2-methyl-3-pyridinyl]ethyl]-6,7-difluoro- (CA INDEX NAME)



RN 942938-14-9 HCAPLUS


CN 1H-Benzimidazole-1-acetamide, 7-cyano-N-[1-[6-(1,1-dimethylethyl)-4-methyl-3-pyridinyl]ethyl]- (CA INDEX NAME)






RN 942938-15-0 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[1-[2-chloro-6-(1,1-dimethylethyl)-3-pyridinyl]ethyl]-7-cyano- (CA INDEX NAME)




RN 942938-16-1 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, 7-cyano-N-[1-[6-(1,1-dimethylethyl)-3-pyridinyl]ethyl]- (CA INDEX NAME)




RN 942938-17-2 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[1-[6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-pyridinyl]ethyl]-7-nitro- (CA INDEX NAME)




RN 942938-18-3 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[1-[5-(1,1-dimethylethyl)-2-pyridinyl]ethyl]-7-fluoro- (CA INDEX NAME)




RN 942938-19-4 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[1-[6-(2-fluoroethoxy)-3-pyridinyl]ethyl]-7-nitro- (CA INDEX NAME)



RN 942938-79-6 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, 7-nitro-N-[1-[4-(2,2,2-trifluoroethoxy)phenyl]ethyl]- (CA INDEX NAME)



IT 942938-26-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of benzimidazole compds. useful in therapy of VR1 - mediated diseases)

RN 942938-26-3 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[(1S)-1-(4-hydroxyphenyl)ethyl]-7-nitro- (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:298140 HCAPLUS

DOCUMENT NUMBER: 144:331439

TITLE: Preparation of benzimidazol-1-yl-substituted alkanolic acid amides as vanilloid receptor 1 antagonists with analgesic and other therapeutic potential

INVENTOR(S): Besidski, Yevgeni; Kers, Inger; Nyloef, Martin; Slaitas, Andis

PATENT ASSIGNEE(S): AstraZeneca AB, Swed.

SOURCE: PCT Int. Appl., 84 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006033620	A1	20060330	WO 2005-SE1364	20050919
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2005285656	A1	20060330	AU 2005-285656	20050919
CA 2577818	A1	20060330	CA 2005-2577818	20050919
EP 1797067	A1	20070620	EP 2005-783773	20050919
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR			
CN 101023071	A	20070822	CN 2005-80031737	20050919
IN 2007DN01584	A	20070803	IN 2007-DN1584	20070227
KR 2007056104	A	20070531	KR 2007-706447	20070321
NO 2007002005	A	20070615	NO 2007-2005	20070419
PRIORITY APPLN. INFO.:			SE 2004-2284	A 20040921
			WO 2005-SE1364	W 20050919
OTHER SOURCE(S):			CASREACT 144:331439; MARPAT 144:331439	
GI				




AB The present invention relates to benzimidazol-1-yl-substituted alkanolic acid amides (shown as I; variables defined below; e.g. 2-(7-amino-1H-benzimidazol-1-yl)-N-(4-tert-butylbenzyl)acetamide (II)) or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compns. containing said compds. and to the use of said compds. in therapy. For I: R1 is H, NO2, halo, NR6R7, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C1-6haloalkylo, R6OC0-6alkyl, R6CO, R6OCO or CONR6R7; m = 0-3; R2 is H, NO2, halo, NR6R7, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C1-6haloalkylo, cyano, R6OC0-6alkyl, R6CO, R6OCO, R6CONR7, R6R7NCO, R8SO2, R8SO2HN, arylC0-6alkyl or heteroarylC0-6alkyl; R3 and R9 = H or C1-4alkyl; R2 and R3 optionally form a ring; p = 0-2; n = 0, 2, 3 or 4; R5 is C1-10alkyl, C6-10arylC0-6alkyl, C3-7cycloalkylC0-6alkyl or C5-6heteroarylC0-6alkyl, whereby any aryl, heteroaryl or cycloalkyl may be fused with aryl, heteroaryl, C3-7cycloalkyl or C3-7heterocycloalkyl, and which R5 may be substituted with  $\geq 1$  A; A is H, OH, NO2, cyano, R6CO, R6O(CO), halo, C1-6alkyl, NR6R7, C1-6haloalkyl, C1-6haloalkylo, R6OC0-6alkyl, hydroxyC1-6alkyl, R8SO2, R8SO2HN, C5-6arylo or CONR6R7; R6 and R7 = H or C1-6alkyl; and R8 is NR6R7 or C1-4alkyl. Although the

methods of preparation are not claimed, preps. and/or characterization data for 65 examples of I are included. Many of the examples were prepared from a 7-substituted (1H-benzimidazol-1-yl)acetic acid (preps. described) and an amine in MeCN in the presence of Et<sub>3</sub>N and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate. IC<sub>50</sub> values for 4 examples of I acting as antagonists of the vanilloid receptor 1 in the presence of agonists like capsaicin or 2-(morpholino)ethanesulfonic acid are tabulated.

IT 880882-44-0P, 2-(7-Acetyl-1H-benzimidazol-1-yl)-N-(4-tert-butylbenzyl)acetamide 880882-58-6P, 2-(7-Amino-1H-benzimidazol-1-yl)-N-(4-tert-butylbenzyl)acetamide  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidate; preparation of benzimidazol-1-yl-substituted alkanolic acid amides as vanilloid receptor 1 antagonists with analgesic and other therapeutic potential)  
 RN 880882-44-0 HCAPLUS  
 CN 1H-Benzimidazole-1-acetamide, 7-acetyl-N-[[4-(1,1-dimethylethyl)phenyl]methyl]- (CA INDEX NAME)



RN 880882-58-6 HCAPLUS  
 CN 1H-Benzimidazole-1-acetamide, 7-amino-N-[[4-(1,1-dimethylethyl)phenyl]methyl]- (CA INDEX NAME)



IT 880882-28-0P, 2-(7-Nitro-1H-benzimidazol-1-yl)-N-(3,4,5-trimethoxybenzyl)acetamide 880882-29-1P, N-(3,4-Difluorobenzyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide 880882-30-4P, N-[2-(4-Methoxyphenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide 880882-31-5P, N-[2-(3-Fluorophenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide 880882-32-6P, N-[2-(3-Methoxyphenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide 880882-33-7P, 2-(7-Nitro-1H-benzimidazol-1-yl)-N-[2-[3-(trifluoromethyl)phenyl]ethyl]acetamide 880882-34-8P, N-[2-(3,4-Dimethoxyphenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide 880882-35-9P, N-[2-(3,5-Dimethoxyphenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide 880882-37-1P, N-[2-(5-Bromo-2-methoxyphenyl)ethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide 880882-38-2P, N-[1-(4-Chlorobenzyl)-2-hydroxyethyl]-2-(7-nitro-1H-benzimidazol-1-yl)acetamide 880882-39-3P, N-(2-Hydroxy-2-phenylethyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide 880882-49-5P, N-(4-tert-Butylbenzyl)-2-(7-cyano-1H-benzimidazol-1-


yl)acetamide 880882-55-3P, N-(4-tert-Butylbenzyl)-2-[7-(pyridin-2-yl)-1H-benzimidazol-1-yl]acetamide 880882-59-7P, N-(4-tert-Butylbenzyl)-2-(7-iodo-1H-benzimidazol-1-yl)acetamide 880882-62-2P, N-(4-tert-Butylbenzyl)-2-[7-(1-hydroxyethyl)-1H-benzimidazol-1-yl]acetamide 880882-71-3P, Ethyl 1-[2-[(4-tert-butylbenzyl)amino]-2-oxoethyl]-1H-benzimidazole-7-carboxylate

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzimidazol-1-yl-substituted alkanolic acid amides as vanilloid receptor 1 antagonists with analgesic and other therapeutic potential)


RN 880882-28-0 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, 7-nitro-N-[(3,4,5-trimethoxyphenyl)methyl]- (CA INDEX NAME)




RN 880882-29-1 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[(3,4-difluorophenyl)methyl]-7-nitro- (CA INDEX NAME)



RN 880882-30-4 HCAPLUS


CN 1H-Benzimidazole-1-acetamide, N-[2-(4-methoxyphenyl)ethyl]-7-nitro- (CA INDEX NAME)



RN 880882-31-5 HCAPLUS


CN 1H-Benzimidazole-1-acetamide, N-[2-(3-fluorophenyl)ethyl]-7-nitro- (CA INDEX NAME)

10556229a.trn




RN 880882-32-6 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[2-(3-methoxyphenyl)ethyl]-7-nitro- (CA INDEX NAME)




RN 880882-33-7 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, 7-nitro-N-[2-[3-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)



RN 880882-34-8 HCAPLUS


CN 1H-Benzimidazole-1-acetamide, N-[2-(3,4-dimethoxyphenyl)ethyl]-7-nitro- (CA INDEX NAME)



RN 880882-35-9 HCAPLUS


CN 1H-Benzimidazole-1-acetamide, N-[2-(3,5-dimethoxyphenyl)ethyl]-7-nitro- (CA INDEX NAME)

10556229a.trn




RN 880882-37-1 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[2-(5-bromo-2-methoxyphenyl)ethyl]-7-nitro-  
(CA INDEX NAME)




RN 880882-38-2 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[2-(4-chlorophenyl)-1-(hydroxymethyl)ethyl]-7-nitro-  
(CA INDEX NAME)




RN 880882-39-3 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-(2-hydroxy-2-phenylethyl)-7-nitro- (CA  
INDEX NAME)




RN 880882-49-5 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, 7-cyano-N-[[4-(1,1-dimethylethyl)phenyl]methyl]-  
(CA INDEX NAME)




RN 880882-55-3 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[[4-(1,1-dimethylethyl)phenyl]methyl]-7-(2-pyridinyl)- (CA INDEX NAME)




RN 880882-59-7 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[[4-(1,1-dimethylethyl)phenyl]methyl]-7-iodo- (CA INDEX NAME)



RN 880882-62-2 HCAPLUS


CN 1H-Benzimidazole-1-acetamide, N-[[4-(1,1-dimethylethyl)phenyl]methyl]-7-(1-hydroxyethyl)- (CA INDEX NAME)




RN 880882-71-3 HCAPLUS

CN 1H-Benzimidazole-7-carboxylic acid, 1-[2-[[[4-(1,1-dimethylethyl)phenyl]methyl]amino]-2-oxoethyl]-, ethyl ester (CA INDEX NAME)






IT 796973-43-8, 2-(7-Nitro-1H-benzimidazol-1-yl)-N-(4-tert-butylbenzyl)acetamide 880882-72-4, 1-[2-[[4-tert-Butylbenzyl]amino]-2-oxoethyl]-1H-benzimidazole-7-carboxylic acid  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of benzimidazol-1-yl-substituted alkanolic acid amides as vanilloid receptor 1 antagonists with analgesic and other therapeutic potential)  
 RN 796973-43-8 HCAPLUS  
 CN 1H-Benzimidazole-1-acetamide, N-[[4-(1,1-dimethylethyl)phenyl]methyl]-7-nitro- (CA INDEX NAME)



RN 880882-72-4 HCAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[2-[[[4-(1,1-dimethylethyl)phenyl]methyl]amino]-2-oxoethyl]- (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1103734 HCAPLUS

DOCUMENT NUMBER: 143:386764

TITLE: Preparation of aniline derivatives as kininogenase inhibitors

INVENTOR(S): Tokumasu, Munetaka; Sugiki, Masayuki; Hirashima, Haruko; Matsumoto, Hideki; Yoshimura, Toshihiko; Nogi, Yasuko; Takahashi, Mitsuo; Kitazawa, Manabu; Oonuki, Akiko; Fukuchi, Naoyuki; Shima, Yoichiro

PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan; et al.


SOURCE: PCT Int. Appl., 137 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005095327	A1	20051013	WO 2005-JP6834	20050331
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:				
BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1736465	A1	20061227	EP 2005-728768	20050331
R:				
AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
US 2007066586	A1	20070322	US 2006-537139	20060929
PRIORITY APPLN. INFO.:			JP 2004-107368	A 20040331
			WO 2005-JP6834	W 20050331
OTHER SOURCE(S):	MARPAT 143:386764			
GI				



AB The title compds., e.g. I [X = C, N ; M = H, halo, (un)substituted alkyl, etc.; Z = single bond, CH:CH, CO, etc.; B = H, (un)substituted alkyl, etc.; R3 = H, (un)substituted alkyl, (un)substituted aryl; further detail on R3 is given; Y = CO, SO2; R1a, R1b = H, (un)substituted alkyl, (un)substituted aryl; further detail on R1a and R1b is given; R2 = H, alkyl; further detail related to R1a, R1b and R2 is given; n = 0 or 1; R6 and R60 = H, (un)substituted alkyl, amino, etc.], are prepared Thus, N-((2R)-3-methyl-2-[[4-(trifluoromethyl)phenyl]-amino]butyl)-2-phenylacetamide CF3CO2H salt was prepared in 3 steps from 4-trifluoromethyliodobenzene and D-valine. In an in vitro test for tissue kallikrein inhibiting activity, compds. of this invention showed pIC50 values of 6.51 to 7.70. In a test for analgesic activity using mice, compds. of this invention at 30 mg/kg orally showed activity equal to that of indomethacin at 10 mg/kg orally.


IT 866830-42-4P 866830-44-6P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of aniline derivs. as kininogenase inhibitors)

10556229a.trn

RN 866830-42-4 HCAPLUS

CN 1H-Benzimidazole-7-carboxylic acid, 1-[2-[[[(2R)-3-methyl-2-[[4-(trifluoromethyl)phenyl]amino]butyl]amino]-2-oxoethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 866830-44-6 HCAPLUS

CN 1H-Benzimidazole-7-carboxylic acid, 1-[2-[[[(2R)-3-methyl-2-[[4-(trifluoromethyl)phenyl]amino]butyl]amino]-2-oxoethyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2007 ACS ON STN

ACCESSION NUMBER: 2004:1019865 HCAPLUS

DOCUMENT NUMBER: 142:6536

TITLE: A preparation of benzimidazole derivatives, useful as inhibitors of vanilloid receptor 1

INVENTOR(S): Besidski, Yevgeni; Kers, Inger; Nyloef, Martin; Rotticci, Didier; Slaitas, Andis; Svensson, Mats

PATENT ASSIGNEE(S): AstraZeneca AB, Swed.

SOURCE: PCT Int. Appl., 88 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004100865	A2	20041125	WO 2004-SE738	20040513
WO 2004100865	A3	20050120		



W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG


AU 2004238177	A1	20041125	AU 2004-238177	20040513
CA 2525628	A1	20041125	CA 2004-2525628	20040513
EP 1626964	A2	20060222	EP 2004-732865	20040513
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004010316	A	20060523	BR 2004-10316	20040513
CN 1784387	A	20060607	CN 2004-80012619	20040513
JP 2006528971	T	20061228	JP 2006-532186	20040513
IN 2005DN04859	A	20071012	IN 2005-DN4859	20051024
US 2006287377	A1	20061221	US 2005-556229	20051109
MX 2005PA12247	A	20060210	MX 2005-PA12247	20051114
NO 2005005977	A	20060216	NO 2005-5977	20051215
PRIORITY APPLN. INFO.:			SE 2003-1446	A 20030516
			SE 2004-43	A 20040112
			WO 2004-SE738	W 20040513

OTHER SOURCE(S): MARPAT 142:6536  
 GI




AB The invention relates to a preparation of new benzimidazole derivs. of formula I [wherein: X is CH<sub>2</sub> or (CH<sub>2</sub>)<sub>2-4</sub>; Y is H or (alkyl)<sub>0-2</sub>; R<sub>1</sub> is H, NO<sub>2</sub>, halogen, alk(en/yn)yl, or (H/alkyl)C(O), etc.; R<sub>2</sub> is NO<sub>2</sub>, halogen, alk(en/yn)yl, or haloalkyl, etc.; R<sub>3</sub> is alkyl, arylalkyl, cycloalkylalkyl, or heteroarylalkyl, etc.; R<sub>4</sub> is H or alkyl], useful as inhibitors of vanilloid receptor 1 (VR 1). For instance, benzimidazole derivative II was prepared via amidation of 2-(7-nitro-1H-benzimidazol-1-yl)acetic acid by 3,5-difluoroaniline. The prepared title compds. were screened in fluorometric image plate reader assay (hVR1 FLIPR) (II, IC<sub>50</sub> = 50 nM).


IT 796973-17-6P, N-Hexyl-2-(7-nitro-1H-benzimidazol-1-yl)acetamide  
 796973-21-2P, N-(2-Bromobenzyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide 796973-22-3P, 2-(7-Nitro-1H-benzimidazol-1-yl)-N-[3-(trifluoromethyl)benzyl]acetamide 796973-34-7P,  
 2-(7-Nitro-1H-benzimidazol-1-yl)-N-[2-(trifluoromethyl)benzyl]acetamide 796973-42-7P, 2-(7-Nitro-1H-benzimidazol-1-yl)-N-[4-(trifluoromethyl)benzyl]acetamide 796973-43-8P,  
 N-(4-tert-Butylbenzyl)-2-(7-nitro-1H-benzimidazol-1-yl)acetamide 796973-45-0P, 2-(7-Nitro-1H-benzimidazol-1-yl)-N-[4-(trifluoromethoxy)benzyl]acetamide 796973-68-7P, Methyl  
 1-[2-[(4-tert-butylbenzyl)amino]-2-oxoethyl]-1H-benzimidazole-7-carboxylate 796973-78-9P, N-(4-tert-Butylbenzyl)-2-[7-(trifluoromethyl)-1H-benzimidazol-1-yl]acetamide 796973-82-5P,  
 N-(4-tert-Butylbenzyl)-2-(7-fluoro-1H-benzimidazol-1-yl)acetamide  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of new benzimidazole derivs. useful as inhibitors of vanilloid receptor 1)  
 RN 796973-17-6 HCAPLUS  
 CN 1H-Benzimidazole-1-acetamide, N-hexyl-7-nitro- (CA INDEX NAME)




RN 796973-21-2 HCAPLUS  
 CN 1H-Benzimidazole-1-acetamide, N-[(2-bromophenyl)methyl]-7-nitro- (CA INDEX NAME)




RN 796973-22-3 HCAPLUS  
 CN 1H-Benzimidazole-1-acetamide, 7-nitro-N-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 796973-34-7 HCAPLUS  
 CN 1H-Benzimidazole-1-acetamide, 7-nitro-N-[[2-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 796973-42-7 HCAPLUS  
CN 1H-Benzimidazole-1-acetamide, 7-nitro-N-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 796973-43-8 HCAPLUS  
CN 1H-Benzimidazole-1-acetamide, N-[[4-(1,1-dimethylethyl)phenyl]methyl]-7-nitro- (CA INDEX NAME)




RN 796973-45-0 HCAPLUS  
CN 1H-Benzimidazole-1-acetamide, 7-nitro-N-[[4-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)




RN 796973-68-7 HCAPLUS  
CN 1H-Benzimidazole-7-carboxylic acid, 1-[2-[[[4-(1,1-dimethylethyl)phenyl]methyl]amino]-2-oxoethyl]-, methyl ester (CA INDEX NAME)

10556229a.trn




RN 796973-78-9 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[[4-(1,1-dimethylethyl)phenyl]methyl]-7-(trifluoromethyl)- (CA INDEX NAME)



RN 796973-82-5 HCAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[[4-(1,1-dimethylethyl)phenyl]methyl]-7-fluoro- (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
34.15	206.46

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-3.90	-3.90

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 10:20:16 ON 09 NOV 2007